We know that the development and progression of invasive lobular carcinoma (ILC) are characterized by the loss of E-cadherin–E-cadherin binding in normal cells that prevents beta-catenin inhibition of PTEN, thus permitting the inhibition of AKT [19]. The gene discussed is CTNNB1; the disease is invasive lobular breast carcinoma.